MMV and Anacor join hands in hunt for new antimalarial compounds

MMV and California based Anacor Pharmaceuticals have agreed to explore Anacor’s novel boron chemistry platform for developing new therapeutics for the treatment of malaria.

26 Apr 2010

Anacor Pharmaceuticals today announced that it has entered into a research agreement with not-for-profit Medicines for Malaria Venture (MMV) to explore Anacor’s novel boron chemistry platform for developing new therapeutics for the treatment of malaria. Under the agreement, Anacor will be responsible for leading the research effort and MMV will contribute its extensive malaria drug research expertise as well as financial support.